within Pharmacolibrary.Drugs.ATC.C;

model C03CA03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 7.5 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 6 / 1000000,
    adminCount     = 1,
    Vd             = 0.012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0031666666666666666,
    Tlag           = 6.0
  );

  annotation(Documentation(
    info ="<html><body><p>Piretanide is a loop diuretic used primarily for the treatment of edema associated with congestive heart failure and, in some cases, hypertension. It acts on the thick ascending limb of the loop of Henle in the kidney to inhibit sodium and chloride reabsorption. Piretanide is approved for use in several European countries but is not available in the United States.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following a single 6 mg oral dose.</p><h4>References</h4><ol><li><p>Ruf, G, et al., &amp; Jähnchen, E (1994). Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination. <i>European journal of clinical pharmacology</i> 46(6) 545–550. DOI:<a href=&quot;https://doi.org/10.1007/BF00196113&quot;>10.1007/BF00196113</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7995323/&quot;>https://pubmed.ncbi.nlm.nih.gov/7995323</a></p></li><li><p>Berg, KJ, et al., &amp; Bergh, K (1983). The pharmacokinetics and diuretic effects of piretanide in chronic renal insufficiency. <i>British journal of clinical pharmacology</i> 15(3) 347–353. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1983.tb01509.x&quot;>10.1111/j.1365-2125.1983.tb01509.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6342640/&quot;>https://pubmed.ncbi.nlm.nih.gov/6342640</a></p></li><li><p>Noormohamed, FH, et al., &amp; Lant, AF (1990). Renal responses and pharmacokinetics of piretanide in humans: effect of route of administration, state of hydration and probenecid pretreatment. <i>The Journal of pharmacology and experimental therapeutics</i> 254(3) 992–999. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2395126/&quot;>https://pubmed.ncbi.nlm.nih.gov/2395126</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C03CA03;
